Indoco Remedies Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2025, recommended Final Dividend of 0.20 per equity share.
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies' board recommended a final dividend of Rs. 0.20 per equity share (10% on face value of Rs. 2) for FY25, subject to shareholder approval. However, the audited results for the year were weak — standalone revenue from operations fell about 15% to Rs. 1,49,478 lakhs (from Rs. 1,76,195 lakhs in FY24) and the company reported a standalone loss of Rs. 873 lakhs versus a profit of Rs. 11,664 lakhs a year earlier. On a consolidated basis, revenue declined to Rs. 1,64,129 lakhs and the group posted a loss of Rs. 2,795 lakhs against a Rs. 9,701 lakh profit in FY24. The statutory auditor issued an unmodified opinion but added an Emphasis of Matter flagging material uncertainty around the going concern of two subsidiaries — FPP Holding LLC (net loss Rs. 2,809.58 lakhs, negative net worth Rs. 2,320.41 lakhs) and Warren Remedies Pvt Ltd (net loss Rs. 3,776.53 lakhs, negative net worth Rs. 3,204.66 lakhs).
The dividend is small (Rs. 0.20 per share) and unlikely to meaningfully support the stock given the swing to a loss, double-digit revenue decline, and auditor's going-concern flag on overseas and domestic subsidiaries. Shareholders should weigh the weak operating performance and subsidiary stress against the modest payout.